View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Edwards Lifesciences to Host Earnings Conference Call on April 25, 202...

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at . About Edwards Lifesciences Edwards Lifesciences, is the global leader of patient-focused innovations for structural heart d...

 PRESS RELEASE

Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare...

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen Healthcare Conference on Tuesday, March 5, 2024. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, are scheduled to present at 10:30 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at , with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the global leader of patient-focused innovations for structural he...

 PRESS RELEASE

Edwards Lifesciences Reports Fourth Quarter Results

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2023. Highlights and Outlook Q4 sales grew 14 percent to $1.53 billion; constant currency1 sales grew 13 percent Q4 TAVR sales grew 13 percent; constant currency sales grew 12 percent Q4 EPS of $0.61; adjusted1 EPS of $0.64 2023 sales of $6.0 billion grew 12 percent; EPS of $2.30; adjusted EPS of $2.51 Completed enrollment early in PROGRESS pivotal trial, studying moderate AS patients Received early FDA approval for EVOQUE; ongoing European l...

 PRESS RELEASE

Edwards Lifesciences to Host Earnings Conference Call on February 6, 2...

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2023 after the market closes on Tuesday, February 6, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at . About Edwards Lifesciences Edwards Lifesciences, is the global leader of patient-focused innovations for structural hea...

Moody's says Edward's planned spinoff of its Critical Care business re...

Moody's Investors Service ("Moody's") said that Edwards Lifesciences Corporation's ("Edwards") announced spin-off of its Critical Care Business will reduce the company's overall diversity and scale. The Critical Care business represents approximately 15% of Edwards' total revenue (year-to-date as of...

Edwards Lifesciences Corporation: Update to credit analysis

Our credit view of this issuer reflects its excellent liquidity and solid performance aided by focus on innovation, against its limited scale relative to competitors.

Edwards Lifesciences Corp: 3 directors

Three Directors at Edwards Lifesciences Corp sold/sold after exercising options 87,875 shares at between 88.625USD and 88.945USD. The significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trade...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

"Sell in May" Another Reason to Favor Defensives The S&P 500 made a high of 4169 last week, tagging our 4165-4200 resistance range. We still believe 4165-4200 will cap upside in 2023, with a reach to 4300-4325 also within the realm of possibility. Considering limited upside in both scenarios, and with the seasonably weaker "sell in May and go away" period approaching, we continue to recommend higher allocations to defensives including Utilities (XLU, RYU), Consumer Staples (XLP), Health Care (X...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion ETF Pathfinder: Actionable ETF research & Ideas

Rally Continues as USD & 10-Year Treasury Yield Break We continue to believe the market remains in bear market rally mode, though the Russell 2000 (IWM) has already achieved our price target at its 200-day MA, while the S&P 500 is only 2% away from hitting its 200-day MA. We have said that this is still a bear market as long as the S&P 500 and IWM are below their 200-day MAs, but, as we discussed in our Oct. 31 ETF Pathfinder, we continue to see signs that suggest reversals could be coming. Ma...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Edwards Lifesciences Corporation: Update to credit analysis

Our credit view of this issuer reflects its excellent liquidity and its solid performance aided by focus on innovation, against its limited scale relative to competitors.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch